{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T14:32:32Z","timestamp":1720362752539},"reference-count":26,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"40","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American Society of Clinical Oncology Educational Book"],"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:p> Recent clinical trials have addressed the notion of early treatment of smoldering multiple myeloma (SMM). The results evidence improvement in progression-free survival and, in one study, overall survival. Although the treatment of SMM can be considered under specific circumstances, we propose here that careful interpretation of the clinical trials and the patient-specific data are needed before recommending therapy. In particular, many questions remain regarding the best regimen to be used as well as how to adapt based on the underlying disease biology. Hematologists should have a very thorough understanding of models designed to predict the progression from SMM to multiple myeloma, because their correct interpretation is paramount to establish proper care. Although there is no doubt that treatment should be started before overt end-organ damage, we do not believe that the current data support the widespread treatment of all SMM. <\/jats:p>","DOI":"10.1200\/edbk_280179","type":"journal-article","created":{"date-parts":[[2020,3,24]],"date-time":"2020-03-24T14:03:00Z","timestamp":1585058580000},"page":"364-370","source":"Crossref","is-referenced-by-count":5,"title":["Treatment of Smoldering Multiple Myeloma: Expectant Observation Should Still Be the Standard"],"prefix":"10.1200","author":[{"given":"Rafael","family":"Fonseca","sequence":"first","affiliation":[{"name":"Mayo Clinic, Phoenix, AZ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Gonzalez-Velez","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Phoenix, AZ"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"bibr1-EDBK_280179","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198006123022405"},{"key":"bibr2-EDBK_280179","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070389"},{"key":"bibr3-EDBK_280179","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.764419"},{"key":"bibr4-EDBK_280179","doi-asserted-by":"publisher","DOI":"10.4065\/78.1.21"},{"key":"bibr5-EDBK_280179","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1158\/1078-0432.CCR-15-2981","volume":"22","author":"Fonseca R","year":"2016","journal-title":"Clin Cancer Res"},{"key":"bibr6-EDBK_280179","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-108357"},{"key":"bibr7-EDBK_280179","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41581-018-0077-4","volume":"15","author":"Leung N","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"bibr8-EDBK_280179","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1756-9966-27-11","volume":"27","author":"Sonmez M","year":"2008","journal-title":"J Exp Clin Cancer Res"},{"key":"bibr9-EDBK_280179","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.12.1909"},{"key":"bibr10-EDBK_280179","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1182\/blood.V87.4.1495.bloodjournal8741495","volume":"87","author":"Alsina M","year":"1996","journal-title":"Blood"},{"key":"bibr11-EDBK_280179","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"bibr12-EDBK_280179","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0077-4"},{"key":"bibr13-EDBK_280179","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-05-088443"},{"key":"bibr14-EDBK_280179","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.237"},{"key":"bibr15-EDBK_280179","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/leu.2016.205","volume":"31","author":"Gonsalves WI","year":"2017","journal-title":"Leukemia"},{"key":"bibr16-EDBK_280179","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/j.1365-2141.2012.09241.x","volume":"158","author":"Sanchez E","year":"2012","journal-title":"Br J Haematol"},{"key":"bibr17-EDBK_280179","volume":"37","author":"Dispenzieri A","year":"2019","journal-title":"J Clin Oncol"},{"key":"bibr18-EDBK_280179","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.8000"},{"key":"bibr19-EDBK_280179","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.3324\/haematol.2015.124651","volume":"100","author":"Khan R","year":"2015","journal-title":"Haematologica"},{"key":"bibr20-EDBK_280179","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.060780"},{"key":"bibr21-EDBK_280179","doi-asserted-by":"publisher","DOI":"10.4065\/mcp.2009.0653"},{"key":"bibr22-EDBK_280179","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1300439"},{"key":"bibr23-EDBK_280179","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30124-3"},{"key":"bibr24-EDBK_280179","author":"Lonial S","journal-title":"J Clin Oncol"},{"key":"bibr25-EDBK_280179","doi-asserted-by":"crossref","unstructured":"Mateos MV. Curative strategy (GEM-CESAR) for high-risk smoldering myeloma: carfilzomib, lenalidomide and dexamethasone (KRd) as induction followed by HDT-ASCT consolidation with KRd and maintenance with Rd. Presented at: 24th Congress of EHA. Amsterdam, Netherlands; 2019. Abstract S871.","DOI":"10.1097\/01.HS9.0000561764.53887.c0"},{"key":"bibr26-EDBK_280179","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1182\/blood-2019-126094","volume":"134","author":"Harrison S","year":"2019","journal-title":"Blood"}],"container-title":["American Society of Clinical Oncology Educational Book"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/EDBK_280179","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T10:15:21Z","timestamp":1653819321000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/EDBK_280179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":26,"journal-issue":{"issue":"40","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["10.1200\/EDBK_280179"],"URL":"https:\/\/doi.org\/10.1200\/edbk_280179","relation":{},"ISSN":["1548-8748","1548-8756"],"issn-type":[{"value":"1548-8748","type":"print"},{"value":"1548-8756","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5]]}}}